Argenx
ARGX
#591
Rank
NZ$58.27 B
Marketcap
$958.93
Share price
-5.41%
Change (1 day)
17.56%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) - Cash on Hand

Cash on Hand as of June 2024 : NZ$5.28 Billion

According to Argenx 's latest financial reports the company has NZ$5.28 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Argenx - Cash on Hand chart (from 2021 to 2020)

Cash on Hand by year

Year Cash on Hand Change
2022-12-31NZ$3.45 B0.94%
2021-12-31NZ$3.42 B0.52%
2020-12-31NZ$3.40 B36.34%
2019-12-31NZ$2.49 B126.63%
2018-12-31NZ$1.10 B51.04%
2017-12-31NZ$0.72 B372.05%
2016-12-31NZ$0.15 B108.95%
2015-12-31NZ$73.92 M-30.03%
2014-12-31NZ$0.10 B96.07%
2013-12-31NZ$53.88 M53.76%
2012-12-31NZ$35.04 M-30.98%
2011-12-31NZ$50.77 M180.45%
2010-12-31NZ$18.1 M